Know when Premera Bluecross releases new policies or updates existing guidance.
Rules for medical necessity, benefit routing, coding, and authorization lengths for denosumab-brand and biosimilar products for osteoporosis, prevention of skeletal-related events, hypercalcemia of malignancy, giant cell tumor of bone, and related indications; intended for providers and utilization reviewers.
Key ActionObtain prior authorization and document trial and inadequate response or intolerance to required bisphosphonates and designated preferred denosumab products before requesting non-preferred denosumab coverage.
Preferred and non-preferred designations for multiple denosumab products were updated and coverage criteria were changed to require prior inadequate response or intolerance to specified preferred products.
Dose limit for prevention of skeletal-related events in multiple myeloma and bone metastases was set to 120 mg every 4 weeks for specified denosumab products.
New HCPCS codes Q5161 and Q5162 were added to the coding section.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
authorization lengths vary
pharmacy & medicalbenefit routing
Q5161,Q5162new HCPCS codes
Coverage Criteria and Indications
Initial Therapy for Osteoporosis and Bone Mass Increase
Covered when ALL of the following are met:
Indication: Treatment of one of the following: osteoporosis after trial and inadequate response or intolerance to two generic bisphosphonates (either two oral medications or one oral and one IV) unless bisphosphonates are contraindicated; OR to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer; OR to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.prior bisphosphonate trial or contraindication
Generic bisphosphonates include alendronate, ibandronate, risedronate, zoledronic acid.
Prevention of Skeletal-Related Events and Hypercalcemia of Malignancy
Covered when ALL of the following are met:
SRE prevention or hypercalcemia of malignancy: Used for the prevention of skeletal-related events in individuals with multiple myeloma or with bone metastases from solid tumors (for breast cancer: expected survival ≥ 3 months). For treatment of hypercalcemia of malignancy there must be documented inadequate response or intolerance to IV 4 mg zoledronic acid.documented inadequate response/intolerance to IV 4 mg zoledronic acid where specified
Dose limited to 120 mg every 4 weeks for these indications.
Product Line and Step Requirements
Coverage and sequencing requirements among denosumab products:
Biosimilar / product sequencing: Coverage of non-preferred denosumab products requires documented inadequate response or intolerance to the specified preferred denosumab products. Preferred/non-preferred pairings and required prior products vary by target non-preferred product (see policy product-specific sequencing).trial of specified denosumab products
2026 update designated certain products as preferred (e.g., Bildyos, Enoby, Bilprevda, Xtrenbo) and requires prior trial of those preferred agents before non-preferred products.
Covered Indications and Evidence Summary
Covered when indication aligns with FDA‑approved or guideline-supported uses and clinical evidence summarized below:
Postmenopausal osteoporosis: Denosumab reduces radiographic vertebral, nonvertebral, and hip fractures compared with placebo in postmenopausal osteoporotic women.
Supported by randomized trials (policy summary).
Men with osteoporosis (BMD increase): Denosumab increases bone mass in men, including those receiving androgen deprivation therapy; however, trials in men did not demonstrate statistically significant vertebral fracture risk reduction in the two studies reviewed.
Use supported for BMD improvement and ADT-associated bone loss; fracture-reduction evidence limited.
Glucocorticoid-induced osteoporosis: Denosumab was non-inferior and superior to risedronate at 12 months for lumbar spine BMD in glucocorticoid-continuing and initiating populations.
Study included individuals receiving ≥7.5 mg prednisone (or equivalent).
All uses of the denosumab products listed in this policy that are not specifically described in the coverage criteria are considered investigational. Requests for treatment of conditions or indications not outlined in this policy will be evaluated as investigational and are not covered under the medical necessity criteria set forth here.
A systematic review and meta-analysis identified two randomized studies of denosumab versus placebo in men with osteoporosis; neither study demonstrated a statistically significant reduction in vertebral fracture risk for men treated with denosumab, indicating limited evidence for fracture risk reduction in this population.
Use of denosumab for indications or patient groups outside the specific conditions and clinical criteria listed in this policy is considered investigational and therefore not medically necessary. Coverage is limited to the diagnoses and prior‑therapy requirements explicitly described in the criteria.
The available clinical trial data for men do not show conclusive benefit when denosumab is used solely to reduce vertebral fractures; evidence did not demonstrate statistically significant vertebral fracture risk reduction in the two studies reviewed, and therefore fracture‑reduction benefit in men is not established by the cited trials.
Initial Therapy — Dosing and Product Selection
Initial therapy and dosing
Initial dosing and selection criteria:
Osteoporosis dosing: Dose for osteoporosis indications is limited to 60 mg every 6 months.60 mg every 6 months
Oncology / SRE dosing: Dose for prevention of skeletal-related events and specified oncologic indications is limited to 120 mg every 4 weeks.120 mg every 4 weeks
Reauthorization requirements — ALL must be met for continued approval:
Clinical response documentation: Approval may be renewed when chart notes document stabilization or improvement and the individual has not experienced serious or intolerable side effects.chart notes documenting positive clinical response
Authorization durations vary by product (some up to 12 months, others up to 2 years).
Treatment duration and transitions
Treatment duration and transitions — guidance aligned with clinical practice recommendations:
Transition after stopping denosumab: If denosumab therapy is discontinued, individuals should be transitioned to another antiresorptive agent.
Consistent with AACE/ACE guideline: avoid an antiresorptive gap after denosumab discontinuation.
Step Therapy Requirements
Requirement
Details
Prior bisphosphonate trial requirement
For osteoporosis indications, denosumab (listed first- and second-line products) is considered medically necessary only after the individual has tried and had an inadequate response or intolerance to 2 generic bisphosphonates (either 2 oral medications OR 1 oral medication and 1 IV medication), unless bisphosphonates are contraindicated (examples of generic bisphosphonates: alendronate, ibandronate, risedronate, zoledronic acid). Dose for osteoporosis is limited to 60 mg every 6 months.
Bisphosphonate contraindication exception
If bisphosphonate use is contraindicated (in addition to contraindications in product labeling, oral bisphosphonates are considered contraindicated in individuals with esophageal disorders such as achalasia, esophageal stricture, or Barrett's), denosumab may be considered without the bisphosphonate trial requirement when other criteria are met.
Non-preferred product
Required prior preferred biosimilar(s) and failure criterion
Coverage of these non-preferred denosumab products requires documented inadequate response or intolerance to the preferred Bildyos (denosumab-nxxp) AND Enoby (denosumab-qbde) prior denosumab products as specified in the 2026 update.
Coverage of these non-preferred denosumab products requires documented inadequate response or intolerance to the preferred Bilprevda (denosumab-nxxp) AND Xtrenbo (denosumab-qbde) prior denosumab products as specified in the 2026 update. For oncology SRE/hypercalcemia indications, the dose is limited to 120 mg every 4 weeks where applicable.
Dose thresholds — osteoporosis and oncology dose limits
Osteoporosis dose limit60 mg every 6 months (for osteoporosis and bone‑mass increase indications)
Source for osteoporosis dosingPolicy states dose is limited to 60 mg every 6 months for approved osteoporosis indications and related bone‑mass uses.
Oncology / SRE dose limit120 mg every 4 weeks (for prevention of skeletal‑related events and specified oncologic indications)
Source for oncology dosing change2026 Update added dose limit of 120 mg every 4 weeks for prevention of skeletal‑related events in multiple myeloma and bone metastases from solid tumors.
Quantity and Dosing Limits
Denosumab products — dose limits (60 mg or 120 mg as indicated)
Denosumab product dose optionsDose limits for denosumab products are 60 mg or 120 mg depending on indication (60 mg q6 months for osteoporosis; 120 mg q4 weeks for SRE prevention).
Product examples (policy lists)Policy lists multiple denosumab products (e.g., Bildyos, Enoby, Bilprevda, Xtrenbo, Prolia, Xgeva) subject to these dose limits.
Benefit routing noteRouting (pharmacy vs medical) varies by product and indication; medical benefit products are administered by a healthcare professional per policy guidance.
Denosumab products for SRE prevention — oncology dose limit of 120 mg q4 weeks
SRE prevention oncology dose limit120 mg every 4 weeks — dose limit specifically applied to denosumab products when used for prevention of skeletal‑related events in multiple myeloma and bone metastases from solid tumors.
Prior Authorization, Documentation, and Denial Risk
Prior Authorization
Prior Authorization Required
Prior authorization is required for denosumab products. Initial approvals and reauthorization lengths vary by product (see policy effective date). Requests for non-preferred denosumab products require documented trials of the designated preferred products and demonstration of inadequate response or intolerance.
Prior authorization required for denosumab products
Initial and reauthorization lengths depend on product (see policy for specific durations)
Non-preferred products require prior trial(s) of the specified preferred denosumab products
Documentation Required
Required Medical Record Documentation
Documentation submitted with the prior authorization request must include clear medical record evidence that the medical necessity criteria are met.
Office visit notes that contain the diagnosis and medication history
Site of Care and Billing Guidance
Note
Benefit routing and administration vary by product (office/infusion center/medical)
Some denosumab products are managed through the medical benefit and are administered subcutaneously by a health care professional; benefit routing and administration setting depend on the specific product.
Products listed (e.g., Bildyos, Prolia) are administered by an HCP every six months and may be managed via medical or pharmacy benefit.
Other products (e.g., Aukelso, Bilprevda, Xgeva, Xtrenbo) are managed through the medical benefit.
Billing Rule
Infusion/medical billing may use HCPCS Q-codes (including Q5161/Q5162) or J3590 where applicable
When administered in an infusion/medical setting, billing may use HCPCS codes including the listed Q-codes (e.g., new Q5161, Q5162) or J-codes (J0897) and unclassified biologics codes (J3590) consistent with site-of-care billing guidance; use J3590 where appropriate for listed products.
Biosimilar and Reference Product Designations
Note
Multiple biosimilars and branded denosumab products have first- and second-line designations; coverage depends on indication
The policy lists multiple branded and biosimilar denosumab products with first-line and second-line (preferred/non-preferred) designations; which product is covered first-line depends on the indication and the product-specific preferred status.
First-line examples include Bildyos and Enoby for certain osteoporosis indications; Bilprevda and Xtrenbo are preferred for SRE prevention.
Coverage depends on indication and documented prior therapies per the policy.
Billing Rule
Preferred denosumab products must be tried before other denosumab products
Designated preferred denosumab products (e.g., Bildyos/Enoby or Bilprevda/Xtrenbo depending on indication) must be tried and shown to be inadequate or not tolerated before other denosumab products will be covered.
The 2026 update changed several products to preferred status and requires documented inadequate response or intolerance to those preferred agents before covering non-preferred products.
See product-specific sequencing in the policy for exact required preferred pairings.
Definitions and Key Terms
Osteoporosis — definition and clinical context
DefinitionOsteoporosis: a condition of reduced bone mass and increased fracture risk due to imbalance between bone formation and resorption.
Clinical goalThe goal of therapy for osteoporosis is to prevent fractures by increasing bone mass and reducing fracture risk.
When denosumab is usedDenosumab may be considered medically necessary for osteoporosis after inadequate response or intolerance to two generic bisphosphonates (2 oral or 1 oral + 1 IV), or to increase bone mass in specific high‑risk populations (men on ADT; women on adjuvant aromatase inhibitors).
Skeletal-related events (SREs) — definition and oncology trial context
Definition of SREsSkeletal‑related events (SREs): clinical complications from bone metastases (events studied in oncology trials such as pathologic fracture, spinal cord compression, or need for radiation or surgery to bone).
Background and Mechanism
Denosumab is a monoclonal antibody that acts as a RANK ligand (RANKL) inhibitor, blocking RANKL-mediated activation of osteoclasts and thereby reducing bone resorption. Osteoporosis is characterized by an imbalance in bone remodeling—excessive resorption relative to formation—leading to reduced bone mass and increased fracture risk; by inhibiting RANKL, denosumab increases bone mass and reduces bone turnover in approved indications.
Policy Revision History
2026-08-07material_revisionLatest
Operationalized preferred/non-preferred denosumab product sequencing and updated prior authorization criteria to require inadequate response or intolerance to specified preferred denosumab biosimilars (e.g., Bildyos + Enoby or Bilprevda + Xtrenbo depending on product).
2026-03-01material_revision
Added dosing limit for prevention of skeletal-related events: dose limited to 120 mg every 4 weeks for specified denosumab products for multiple myeloma and bone metastases.
Key ActionObtain prior authorization and document trial and inadequate response or intolerance to required bisphosphonates and designated preferred denosumab products before requesting non-preferred denosumab coverage.
Oncology: prevention of SREs / bone metastases: Xgeva demonstrated non-inferiority to zoledronic acid in delaying time to first on-study SRE; for individuals with bone metastases or multiple myeloma, dosing is limited to 120 mg every 4 weeks per updated criteria.120 mg every 4 weeks
Dose limit added in 2026 update.
Adjuvant aromatase inhibitor-associated bone loss: Denosumab improves BMD and reduced clinical fracture risk in trials including ABCSG-18 where time to first clinical fracture was delayed.
Efficacy established in randomized trials.
Preferred product trial for osteoporosis:
For non-preferred denosumab products used for osteoporosis or bone-mass increase, the individual must have tried and had an inadequate response or intolerance to Bildyos (denosumab-nxxp) AND Enoby (denosumab-qbde) unless bisphosphonates are contraindicated and the bisphosphonate requirement applies as specified.
documented inadequate response or intolerance to specified preferred products
Exact product pairs vary by target non-preferred product per 2026 update.
Preferred product trial for oncology/hypercalcemia: For non-preferred denosumab products used for SRE prevention or hypercalcemia of malignancy, the individual must have tried and had an inadequate response or intolerance to Bilprevda (denosumab-nxxp) AND Xtrenbo (denosumab-qbde) where the policy requires those prior agents.documented inadequate response or intolerance to specified preferred products
See policy product-specific sequencing; dose limits apply as indicated.
Duration considerations: Follow guideline-based limits and follow-up; duration and any subsequent therapy should be individualized based on fracture risk, BMD, and clinical response.
AACE/ACE guidance referenced in policy.
Policy change documenting limit
2026 Update: added the 120 mg q4 weeks dose limit for SRE prevention indications.
Supporting clinical contextXgeva clinical data demonstrated non‑inferiority to zoledronic acid for delaying time to first on‑study SRE; dosing capped at 120 mg q4 weeks per updated criteria.
Medical records demonstrating prior therapies tried, dosing, dates, and reason for discontinuation (inadequate response or intolerance)
For osteoporosis: documentation of trial and inadequate response or intolerance to two generic bisphosphonates (either two oral agents or one oral and one IV), unless bisphosphonates are contraindicated
Documentation Required
Required Documentation for Prior Therapy and Dosing
When prior therapy is required by the policy (including biosimilar/brand sequencing), the request must document the specific prior products, doses, dates of administration, and clinical rationale for failure or intolerance.
Specify the exact preferred denosumab products tried (e.g., Bildyos (denosumab-nxxp) AND Enoby (denosumab-qbde) for certain non-preferred products; or Bilprevda (denosumab-nxxp) AND Xtrenbo (denosumab-qbde) for other non-preferred products)
Include dosing and timing of each prior denosumab trial and the clinical reason for inadequate response or intolerance
If bisphosphonate requirement applies, include names, routes (oral vs IV), doses, dates, and reason for failure or intolerance
Step Therapy
Prior Bisphosphonate Requirement (Osteoporosis)
For osteoporosis indications, denosumab will be covered only after a trial and inadequate response or intolerance to two generic bisphosphonates, unless bisphosphonates are contraindicated.
Generic bisphosphonates include alendronate (oral), ibandronate (oral), risedronate (oral), and zoledronic acid (IV)
Two qualifying trials = either two oral agents OR one oral agent and one IV agent
Oral bisphosphonates are considered contraindicated in individuals with specific esophageal disorders (e.g., achalasia, esophageal stricture, Barrett's) in addition to prescribing information contraindications
Step Therapy
Biosimilar Step Sequencing Requirement
The policy includes biosimilar/brand sequencing (step therapy). Approval for non-preferred denosumab products requires documented inadequate response or intolerance to the designated preferred denosumab products named in the policy.
Non-preferred group A (e.g., Boncresa, Bosaya, Conexxence, Jubbonti, Ospomyv, Osvyrti, Prolia, Stoboclo) requires inadequate response or intolerance to Bildyos (denosumab-nxxp) AND Enoby (denosumab-qbde)
Non-preferred group B (e.g., Aukelso, Bomyntra, Jubereq, Osenvelt, Oziltus, Wyost, Xbryk, Xgeva) requires inadequate response or intolerance to Bilprevda (denosumab-nxxp) AND Xtrenbo (denosumab-qbde)
Documentation must match the specific pair required for the non-preferred product requested
Denial Risk
Denial Risk if Prior Therapy or Documentation Requirements Not Met
Failure to provide required prior therapy documentation, dosing details, or rationale for inadequate response/intolerance may result in denial of the request.
Lack of documentation of required bisphosphonate trials for osteoporosis indications may lead to denial
Requests for non-preferred denosumab products will be denied if documentation does not show inadequate response or intolerance to the specific preferred denosumab products required by policy
Ensure submitted records include office visit notes, medication history, dates, doses, and clinical reasons for treatment changes
Relevant HCPCS/Q-codes include J0897, J3590, Q5136, Q5157–Q5159, and new Q5161/Q5162 (added 04/01/26).
Policy lists J3590 parentheticals and advises consistency with site-of-care billing guidance.
Billing Rule
Certain non-preferred products require prior inadequate response to earlier-step preferred agents
Some non-preferred denosumab products were designated as preferred in earlier steps for different non-preferred groups; the policy requires prior inadequate response or intolerance to the earlier-step preferred products before coverage of certain non-preferred formulations.
Examples: Bilprevda and Xtrenbo were set as preferred in certain groups; some non-preferred products require prior inadequate response or intolerance to both Bilprevda AND Xtrenbo.
Refer to the policy's product-specific sequencing language for the exact prior therapy pairings.
Clinical trial context
Xgeva demonstrated non‑inferiority to zoledronic acid in delaying time to first on‑study SRE in multiple myeloma and in trials of breast and castration‑resistant prostate cancer; policy applies a dose limit of 120 mg every 4 weeks for SRE prevention.
Indication scopePolicy applies SRE prevention dosing and criteria to individuals with multiple myeloma or bone metastases from solid tumors (breast cancer requires expected survival ≥3 months).
coding_update
Coding update added new HCPCS codes Q5161 and Q5162 to the coding section, effective April 1, 2026.
2025-11-01new_policy
New denosumab products policy published (approved October 14, 2025) with addition and reorganization of coverage criteria and product listings.